Table 1.
Clinical characteristics
| Characteristics | Patients |
|---|---|
|
N (%) |
|
|
Gender |
|
| Male |
18 (53%) |
| Female |
16 (47%) |
|
Age (median, range) |
60 (29–85) |
|
ECOG PS |
|
| 0 |
2 (6%) |
| 1 |
17 (50%) |
| 2 |
12 (35%) |
| 3 |
3 (9%) |
|
Tumour site |
|
| Stomach |
11 (32.4%) |
| Small Intestine |
10 (29.4%) |
| Mesentery |
7 (20.6%) |
| Other |
6 (17.6%) |
| (peritoneum3, colon 1, rectum 1, oesophagus 1) |
|
|
Metastatic sites |
|
| Liver |
28 (82%) |
| Peritoneum |
25 (73.5%) |
| Lung |
4 (12%) |
| Other |
10 (29.5%) |
|
Transfusion before EPO treatment |
|
| Yes |
10 (29%)/ |
| No |
24 (71%) |
|
Starting Dose of Imatinib/day |
|
| 400 mg |
25(67.6%) |
| 800 mg | 9(11.7%) |